The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...

With the help of prescription medications and a whole lot of moisturizing, it’s possible to keep dermatitis under control.

Clinical Care Options in collaboration with the National Eczema Association is hosting an innovative and engaging symposium IL-13 Inhibition in Moderate to Severe Atopic Dermatitis: A Clinical Skills ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...

Jason B. Pieper, DVM, MS, DACVD, talks about the multiple therapies available for cases of moderate and severe atopic ...

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Patients with mild atopic dermatitis who reported nighttime scratching experienced relief when they used an artificial ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...